SK40898A3 - Use of flt3-ligand, vaccine adjuvants, expand media, a preparation and cells population and method - Google Patents

Use of flt3-ligand, vaccine adjuvants, expand media, a preparation and cells population and method Download PDF

Info

Publication number: SK40898A3
Authority: SK; Slovakia
Prior art keywords: cells; dendritic cells; antigen; csf; ligand
Prior art date: 1995-10-04

Application number

SK408-98A

Other languages

English (en)

Slovak (sk)

Inventor

Kenneth Brasel

Stewart D Lyman

Eugene Maraskovsky

Hilary R Mckenna

David H Lynch

Original Assignee

Immunex Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-04

Filing date

1996-10-03

Publication date

1999-04-13

1996-10-03 Application filed by Immunex Corp filed Critical Immunex Corp

1999-04-13 Publication of SK40898A3 publication Critical patent/SK40898A3/sk

Links

239000012646 vaccine adjuvant Substances 0.000 title claims abstract description 12
229940124931 vaccine adjuvant Drugs 0.000 title claims abstract description 12
108700014844 flt3 ligand Proteins 0.000 title claims description 90
238000000034 method Methods 0.000 title claims description 59
238000002360 preparation method Methods 0.000 title claims description 12
210000004443 dendritic cell Anatomy 0.000 claims abstract description 135
108091007433 antigens Proteins 0.000 claims abstract description 96
102000036639 antigens Human genes 0.000 claims abstract description 96
239000000427 antigen Substances 0.000 claims abstract description 95
210000000130 stem cell Anatomy 0.000 claims abstract description 74
230000028993 immune response Effects 0.000 claims abstract description 36
206010028980 Neoplasm Diseases 0.000 claims abstract description 29
210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 29
210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 26
210000004027 cell Anatomy 0.000 claims description 92
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 52
108010002386 Interleukin-3 Proteins 0.000 claims description 52
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 48
102000000646 Interleukin-3 Human genes 0.000 claims description 41
108010039445 Stem Cell Factor Proteins 0.000 claims description 33
102000004388 Interleukin-4 Human genes 0.000 claims description 26
108090000978 Interleukin-4 Proteins 0.000 claims description 25
230000002708 enhancing effect Effects 0.000 claims description 25
230000001965 increasing effect Effects 0.000 claims description 24
102100040247 Tumor necrosis factor Human genes 0.000 claims description 21
230000004927 fusion Effects 0.000 claims description 20
108090000765 processed proteins & peptides Proteins 0.000 claims description 19
229960005486 vaccine Drugs 0.000 claims description 18
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 17
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 17
238000004519 manufacturing process Methods 0.000 claims description 17
239000000126 substance Substances 0.000 claims description 16
239000008194 pharmaceutical composition Substances 0.000 claims description 15
108090000623 proteins and genes Proteins 0.000 claims description 15
102000004127 Cytokines Human genes 0.000 claims description 10
108090000695 Cytokines Proteins 0.000 claims description 10
239000003446 ligand Substances 0.000 claims description 10
208000035473 Communicable disease Diseases 0.000 claims description 8
201000010099 disease Diseases 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims description 7
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims description 7
201000011510 cancer Diseases 0.000 claims description 7
230000010261 cell growth Effects 0.000 claims description 7
108020001507 fusion proteins Proteins 0.000 claims description 7
102000037865 fusion proteins Human genes 0.000 claims description 7
208000015181 infectious disease Diseases 0.000 claims description 6
230000001613 neoplastic effect Effects 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
102000006354 HLA-DR Antigens Human genes 0.000 claims description 5
108010058597 HLA-DR Antigens Proteins 0.000 claims description 5
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 4
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 4
-1 IL 4 Proteins 0.000 claims description 3
230000003394 haemopoietic effect Effects 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 3
102000015215 Stem Cell Factor Human genes 0.000 claims 3
238000001727 in vivo Methods 0.000 abstract description 16
101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 abstract description 4
102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 abstract description 4
230000003612 virological effect Effects 0.000 abstract description 2
102100020880 Kit ligand Human genes 0.000 description 25
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 22
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 22
239000000203 mixture Substances 0.000 description 18
150000001413 amino acids Chemical group 0.000 description 15
210000005259 peripheral blood Anatomy 0.000 description 14
239000011886 peripheral blood Substances 0.000 description 14
241000699670 Mus sp. Species 0.000 description 10
101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 9
239000002609 medium Substances 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 8
102000055276 human IL3 Human genes 0.000 description 8
239000002671 adjuvant Substances 0.000 description 7
210000003719 b-lymphocyte Anatomy 0.000 description 7
210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 7
239000000463 material Substances 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
239000011324 bead Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
210000001185 bone marrow Anatomy 0.000 description 6
230000003053 immunization Effects 0.000 description 6
238000002649 immunization Methods 0.000 description 6
210000005087 mononuclear cell Anatomy 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
108090001008 Avidin Proteins 0.000 description 5
102000023732 binding proteins Human genes 0.000 description 5
108091008324 binding proteins Proteins 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
102000046157 human CSF2 Human genes 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
108010038379 sargramostim Proteins 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
201000008808 Fibrosarcoma Diseases 0.000 description 4
102100039064 Interleukin-3 Human genes 0.000 description 4
101100335081 Mus musculus Flt3 gene Proteins 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
210000000612 antigen-presenting cell Anatomy 0.000 description 4
238000002617 apheresis Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
230000006698 induction Effects 0.000 description 4
238000002955 isolation Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 3
101000716729 Homo sapiens Kit ligand Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000009471 action Effects 0.000 description 3
239000011149 active material Substances 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
239000001569 carbon dioxide Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
229960002949 fluorouracil Drugs 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
230000036039 immunity Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000003993 interaction Effects 0.000 description 3
229940076264 interleukin-3 Drugs 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
210000000066 myeloid cell Anatomy 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
229960002530 sargramostim Drugs 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
230000001960 triggered effect Effects 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
101000932480 Homo sapiens Fms-related tyrosine kinase 3 ligand Proteins 0.000 description 2
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 2
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
101150052863 THY1 gene Proteins 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000008272 agar Substances 0.000 description 2
230000005975 antitumor immune response Effects 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000002577 cryoprotective agent Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
238000007710 freezing Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
102000055229 human IL4 Human genes 0.000 description 2
238000001802 infusion Methods 0.000 description 2
229940028885 interleukin-4 Drugs 0.000 description 2
229940087875 leukine Drugs 0.000 description 2
230000021633 leukocyte mediated immunity Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000001483 mobilizing effect Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000004044 response Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
RANONBLIHMVXAJ-UHFFFAOYSA-N 4-hydroxycyclophosphamide Chemical compound OC1CCOP(=O)(N(CCCl)CCCl)N1 RANONBLIHMVXAJ-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
102100028471 Eosinophil peroxidase Human genes 0.000 description 1
238000000729 Fisher's exact test Methods 0.000 description 1
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102100022297 Integrin alpha-X Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
108090000177 Interleukin-11 Proteins 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
108090000176 Interleukin-13 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
102000000743 Interleukin-5 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
108010002335 Interleukin-9 Proteins 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
102100033486 Lymphocyte antigen 75 Human genes 0.000 description 1
101710157884 Lymphocyte antigen 75 Proteins 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
230000007022 RNA scission Effects 0.000 description 1
101710146873 Receptor-binding protein Proteins 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000037386 Typhoid Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000011748 cell maturation Effects 0.000 description 1
239000002458 cell surface marker Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000004590 computer program Methods 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000010230 functional analysis Methods 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000000899 immune system response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000002480 immunoprotective effect Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000005210 lymphoid organ Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
239000000693 micelle Substances 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000004224 protection Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000010187 selection method Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000037455 tumor specific immune response Effects 0.000 description 1
201000008297 typhoid fever Diseases 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Hematology (AREA)
Cell Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Virology (AREA)
AIDS & HIV (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK408-98A 1995-10-04 1996-10-03 Use of flt3-ligand, vaccine adjuvants, expand media, a preparation and cells population and method SK40898A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53914295A	1995-10-04	1995-10-04
PCT/US1996/015990 WO1997012633A1 (en)	1995-10-04	1996-10-03	Dendritic cell stimulatory factor

Publications (1)

Publication Number	Publication Date
SK40898A3 true SK40898A3 (en)	1999-04-13

Family

ID=24149974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK408-98A SK40898A3 (en)	1995-10-04	1996-10-03	Use of flt3-ligand, vaccine adjuvants, expand media, a preparation and cells population and method

Country Status (23)

Country	Link
EP (1)	EP0871487B1 (cs)
JP (1)	JP3631496B2 (cs)
KR (2)	KR100514957B1 (cs)
CN (1)	CN1172718C (cs)
AT (1)	ATE432085T1 (cs)
AU (1)	AU697539B2 (cs)
BR (1)	BR9610802A (cs)
CA (1)	CA2232865A1 (cs)
CZ (1)	CZ97798A3 (cs)
DE (1)	DE69637942D1 (cs)
EA (1)	EA199800272A1 (cs)
EE (1)	EE9800105A (cs)
ES (1)	ES2323818T3 (cs)
IS (1)	IS4703A (cs)
LV (1)	LV12085B (cs)
NO (1)	NO981374L (cs)
NZ (1)	NZ321039A (cs)
PL (1)	PL187329B1 (cs)
RO (1)	RO120579B1 (cs)
SI (1)	SI9620116A (cs)
SK (1)	SK40898A3 (cs)
TR (1)	TR199800607T1 (cs)
WO (1)	WO1997012633A1 (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US9068164B1 (en) *	1995-02-02	2015-06-30	Tristem Trading (Cyprus) Limited	Method of preparing an undifferentiated cell
KR20000022445A (ko) *	1996-07-10	2000-04-25	크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카	수상돌기 세포의 활성화 방법
AUPO388396A0 (en) *	1996-11-27	1996-12-19	Ludwig Institute For Cancer Research	Cellular adjuvant
AU7835898A (en) *	1997-06-17	1999-01-04	Immunex Corporation	A method of enhancing antigen-specific peripheral immune tolerance
US6849452B1 (en) *	1998-03-03	2005-02-01	Institut Gustave Roussy	Methods for activating natural killer (NK) cells and means for carrying out said methods
FR2782524B1 (fr) *	1998-08-21	2002-07-19	Roussy Inst Gustave	Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
FR2775692B1 (fr) *	1998-03-03	2000-06-16	Roussy Inst Gustave	Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
DK1077722T3 (da)	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
WO1999062537A1 (en) *	1998-06-04	1999-12-09	The Rockefeller University	Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
US6291661B1 (en)	1998-07-02	2001-09-18	Immunex Corporation	flt3-L mutants and method of use
AU5741699A (en) *	1998-08-27	2000-03-21	Universitatsklinikum Freiburg	Low-molecular fragments of hyaluronic acid for the preparation of vaccines
GB9827604D0 (en) *	1998-12-15	1999-02-10	Lorantis Ltd	Methods of immunosuppression
WO2001009303A2 (en) *	1999-07-30	2001-02-08	Vical Inc.	Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER
AU1358501A (en) *	1999-11-03	2001-05-14	Powderject Vaccines, Inc.	Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US7541184B2 (en)	2000-02-24	2009-06-02	Invitrogen Corporation	Activation and expansion of cells
EP1261366A4 (en) *	2000-02-24	2003-06-18	Univ Leland Stanford Junior	ADJUVANT TREATMENT BY IN VIVO ACTIVATION OF DENDRITIC CELLS
DE60116075T4 (de) *	2000-04-25	2007-06-06	Immunex Corp., Thousand Oaks	Behandlung von tumoren mit photodynamischer therapie
WO2002036141A2 (en) *	2000-11-02	2002-05-10	Immunex Corporation	Method of enhancing lymphocyte-mediated immune responses
WO2002040044A2 (en) *	2000-11-17	2002-05-23	Immunex Corporation	Chemoattractant recruitment of dendritic cells for enhancement of immunization
BRPI0212545B8 (pt) *	2001-09-06	2021-05-25	Northwest Biotherapeutics Inc	método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
KR100490308B1 (ko) *	2002-02-25	2005-05-17	크레아젠 주식회사	면역 치료용 성숙화된 수지상 세포 백신의 제조방법
PL377028A1 (pl) *	2002-03-26	2006-01-23	Immunex Corporation	Sposoby wykorzystania ligandu Flt-3 w procedurach immunizacyjnych
US20050084967A1 (en)	2002-06-28	2005-04-21	Xcyte Therapies, Inc.	Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
KR100522526B1 (ko) *	2002-11-28	2005-10-19	주식회사 바이넥스	면역 치료용 수지상 세포의 제조방법
KR100614220B1 (ko) *	2004-11-08	2006-08-21	고려대학교 산학협력단	Ｆｌｔ3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물
DE102005016234B4 (de) *	2005-04-08	2008-05-15	Tgc Biomics Gmbh	Verfahren zur Einschleusung von exogenem Antigen in den MHC I-Präsentationsweg von Zellen
KR100818215B1 (ko)	2006-10-11	2008-04-01	재단법인서울대학교산학협력재단	Ｃｄ３４양성 줄기세포로부터 ｔ 임파구 전구체를 제조하는 방법
KR101264811B1 (ko)	2011-05-20	2013-05-15	충남대학교산학협력단	마이코박테리움 압세수스의 ＭＡＢ０９８１ｃ 단백질을 이용한 수지상 세포의 성숙방법
CN109563481B (zh) *	2016-07-13	2024-01-05	俄亥俄州创新基金会	用于优化宿主抗原呈递和宿主抗肿瘤和抗病原体免疫的平台和方法
EP3902836B1 (en)	2018-12-18	2026-03-25	Boehringer Ingelheim IO Canada Inc.	Flt3 agonist antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US826250A (en)	1905-12-20	1906-07-17	Albert Huck	Switch for toy railways.
US4714680B1 (en)	1984-02-06	1995-06-27	Univ Johns Hopkins	Human stem cells
US5391485A (en)	1985-08-06	1995-02-21	Immunex Corporation	DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
EP0275598B1 (en)	1986-12-16	1998-01-07	Gist-Brocades N.V.	Molecular cloning and expression of human IL-3
OA09736A (en)	1987-02-18	1993-11-30	Schering Biotech Corp	"Human interleukin-3 and muteins thereof".
JPH03502322A (ja)	1987-10-30	1991-05-30	イミュネックス・コーポレーション	ヒトコロニー形成刺激因子の非グリコシル化類似体
US5108910A (en)	1989-08-22	1992-04-28	Immunex Corporation	DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5073627A (en)	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
EP0676470A1 (en)	1989-10-16	1995-10-11	Amgen Inc.	Stem cell factor
US5199942A (en)	1991-06-07	1993-04-06	Immunex Corporation	Method for improving autologous transplantation
ES2180539T3 (es)	1991-10-23	2003-02-16	Nexell Therapeutics Inc	Metodos para expandir selectivamente celulas madre.
CZ307995A3 (en)	1993-05-24	1996-10-16	Immunex Corp	Ligands for flt3 receptors
US5554512A (en)	1993-05-24	1996-09-10	Immunex Corporation	Ligands for flt3 receptors
US5405772A (en)	1993-06-18	1995-04-11	Amgen Inc.	Medium for long-term proliferation and development of cells

1996
- 1996-10-03 BR BR9610802A patent/BR9610802A/pt unknown
- 1996-10-03 KR KR10-1998-0702286A patent/KR100514957B1/ko not_active Expired - Fee Related
- 1996-10-03 CA CA002232865A patent/CA2232865A1/en not_active Abandoned
- 1996-10-03 KR KR1020047011434A patent/KR100676792B1/ko not_active Expired - Fee Related
- 1996-10-03 PL PL96325964A patent/PL187329B1/pl not_active IP Right Cessation
- 1996-10-03 ES ES96936216T patent/ES2323818T3/es not_active Expired - Lifetime
- 1996-10-03 RO RO98-00824A patent/RO120579B1/ro unknown
- 1996-10-03 WO PCT/US1996/015990 patent/WO1997012633A1/en not_active Ceased
- 1996-10-03 SI SI9620116A patent/SI9620116A/sl unknown
- 1996-10-03 NZ NZ321039A patent/NZ321039A/en unknown
- 1996-10-03 CN CNB96197351XA patent/CN1172718C/zh not_active Expired - Fee Related
- 1996-10-03 AU AU73922/96A patent/AU697539B2/en not_active Ceased
- 1996-10-03 EE EE9800105A patent/EE9800105A/xx unknown
- 1996-10-03 TR TR1998/00607T patent/TR199800607T1/xx unknown
- 1996-10-03 DE DE69637942T patent/DE69637942D1/de not_active Expired - Lifetime
- 1996-10-03 CZ CZ98977A patent/CZ97798A3/cs unknown
- 1996-10-03 SK SK408-98A patent/SK40898A3/sk unknown
- 1996-10-03 AT AT96936216T patent/ATE432085T1/de not_active IP Right Cessation
- 1996-10-03 EP EP96936216A patent/EP0871487B1/en not_active Expired - Lifetime
- 1996-10-03 JP JP51449097A patent/JP3631496B2/ja not_active Expired - Fee Related
- 1996-10-03 EA EA199800272A patent/EA199800272A1/ru unknown
1998
- 1998-03-26 NO NO981374A patent/NO981374L/no unknown
- 1998-03-26 IS IS4703A patent/IS4703A/is unknown
- 1998-04-02 LV LVP-98-63A patent/LV12085B/en unknown

Also Published As

Publication number	Publication date
WO1997012633A1 (en)	1997-04-10
NO981374D0 (no)	1998-03-26
AU7392296A (en)	1997-04-28
RO120579B1 (ro)	2006-04-28
AU697539B2 (en)	1998-10-08
BR9610802A (pt)	1999-07-13
CN1229359A (zh)	1999-09-22
LV12085B (en)	1998-09-20
JP3631496B2 (ja)	2005-03-23
EE9800105A (et)	1998-10-15
ES2323818T3 (es)	2009-07-24
CN1172718C (zh)	2004-10-27
KR100514957B1 (ko)	2005-11-25
CA2232865A1 (en)	1997-04-10
NO981374L (no)	1998-06-03
EP0871487B1 (en)	2009-05-27
SI9620116A (sl)	1999-08-31
NZ321039A (en)	2001-03-30
EA199800272A1 (ru)	1998-10-29
JPH11513389A (ja)	1999-11-16
KR19990063818A (ko)	1999-07-26
EP0871487A1 (en)	1998-10-21
DE69637942D1 (de)	2009-07-09
EP0871487A4 (en)	2004-09-01
IS4703A (is)	1998-03-26
KR20040079421A (ko)	2004-09-14
TR199800607T1 (xx)	1998-06-22
PL325964A1 (en)	1998-08-17
KR100676792B1 (ko)	2007-02-02
ATE432085T1 (de)	2009-06-15
PL187329B1 (pl)	2004-06-30
LV12085A (lv)	1998-07-20
CZ97798A3 (cs)	1999-02-17

Publication	Publication Date	Title
AU697539B2 (en)	1998-10-08	Dendritic cell stimulatory factor
US20090075886A1 (en)	2009-03-19	Dendritic cell stimulatory factor
Liau et al.	1999	Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigens
CA2259140C (en)	2008-09-30	Method of activating dendritic cells
JP2023171524A (ja)	2023-12-01	未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
KR101527260B1 (ko)	2015-06-08	수상세포의 제조방법
US20020155108A1 (en)	2002-10-24	Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
US20030124091A1 (en)	2003-07-03	Endothelial cell derived hematopoietic growth factor
AU758622B2 (en)	2003-03-27	Method for activating natural killer (NK) cells
US7361330B2 (en)	2008-04-22	Methods of using flt3-ligand in the treatment of fibrosarcoma
WO2009066824A1 (en)	2009-05-28	Vaccine comprising monocyte or immature myeloid cells(imc) which were loaded with the ligand of natural killer t cell and antigen
CN1122716C (zh)	2003-10-01	体外细胞培养和移植试剂盒
US7150992B1 (en)	2006-12-19	Methods of preparing dendritic cells with flt3-ligand and antigen
WO2002040647A1 (en)	2002-05-23	Method of establishing cultures of human dendritic cells and use thereof
MXPA98002464A (en)	1998-11-12	Dendrit cellular stimulating factor
US20050048645A1 (en)	2005-03-03	Method of treating or preventing disease characterized by cryptococcus neoformans infection